BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding

British Society for Rheumatology

The prescribing of drugs for pregnant women with rheumatic disease is complicated by a lack of knowledge regarding their compatibility. This may lead to the withdrawal or denial of disease-ameliorating therapies because of a perceived rather than proven risk of their lack of safety in pregnancy. It is important that maternal disease activity is adequately controlled because active rheumatic disease is associated with adverse pregnancy outcomes. There is growing evidence of drug safety in pregnancy that can help address this issue.

This Guidelines summary covers recommendations on prescribing anti-rheumatic drugs, analgesics, and other drugs during pregnancy and breastfeeding.

Log in or register now for FREE in order to:

  • benefit from unlimited access to all pages, including:
    • 180+ guideline summaries
    • 1000+ evidence-based articles
  • review and leave comments on all articles and summaries
  • automatically track your reading and learning via your CPD tracker
  • on-demand webinars presented by leading clinical experts

Registration only takes 2 minutes and it will give you FREE access to all content across:



Need help? Email us